GnRHa妈富隆双降调节方案在IVF/ICSI中的临床观察

目的:探讨妈富隆+GnRHa双降调节对试管婴儿助孕患者临床结局的影响。方法:回顾性分析179例行IVF/ICSI助孕的患者,随机分成A组:82例,监测排卵后1周应用达菲林1.0 mg降调节,B组:97例,月经第5日口服妈富隆,qd,连用21 d,服药第17日应用达菲林1.0 mg降调节,观察A、B组患者降调节结果、Gn用量、Gn用药时间、获卵数、受精率、卵裂率、临床妊娠率、流产率、OHSS发生率及功能性卵巢囊肿情况。结果:A、B组患者Gn日及hCG注射日LH、E2及P水平无统计学意义;Gn用量、用药天数、获卵数、受精率、卵裂率、临床妊娠率、流产率、OHSS发生率也无统计学意义。但B组患者功能性卵巢囊肿形成率明显低于A组,有统计学意义(P<0.05)。结论:IVF-ET中妈富隆双降调节,避免了多次卵泡监测,适合家不在本地的患者,同时避免了卵泡囊肿的发生,也避免了早期妊娠胚胎暴露在GnRHa中。     

来曲唑联合促性腺激素超促排卵用于PCOS患者行IVF-ET的临床研究

目的:研究来曲唑(LE)在多囊卵巢综合征(PCOS)患者超促排卵行IVF-ET中的应用。方法:90例PCOS患者随机分成LE组(n=49)和GnRHa长方案组(对照组,n=41),比较组间的促排卵天数、促性腺激素(Gn)使用剂量、获卵数、受精率、卵裂率、优质胚胎率、种植率和临床妊娠率以及卵巢过度刺激综合征(OHSS)发生率。结果:LE组与对照组的Gn剂量分别为18.0±6.6支和29.3±9.5支,促排卵天数分别为7.8±1.3 d和10.0±1.2 d,获卵数分别为7.9±4.1个和19.8±7.2个,MⅡ卵率分别为74.5%和82.9%,启动周期中-重度OHSS发生率4.1%(2/49)vs 29.3%(12/41),差异均具有统计学意义(P<0.05),而组间的种植率和临床妊娠率(33.3%vs27.5%和51.1%vs 48.5%)差异无统计学意义(P>0.05)。结论:LE用于PCOS超促排卵行IVF-ET与传统的GnRHa长方案相比,在不影响临床妊娠率的前提下,可以有效减少促排卵时间和Gn使用剂量,降低OHSS发生风险,具有极大的临床应用前景。     

HP-hMG在卵巢次高反应患者体外受精周期中的临床应用效果

目的:探讨卵巢次高反应患者体外受精-胚胎移植(in vitro fertilization-embryo transfer,IVF-ET)周期应用高纯度尿促性素(HP-hMG,贺美奇)与重组人卵泡刺激素(r-FSH,果纳芬)促排卵的临床结局。方法:选择IVF-ET助孕的卵巢次高反应患者310例,随机分为A组和B组,分别给予r-FSH+HP-hMG(A组,n=124)和r-FSH(B组,n=186)促排卵,统计促性腺激素(Gn)总用量、Gn使用天数、获卵数、受精率、卵裂率、优质胚胎率、临床妊娠率以及因卵巢过度刺激综合征(OHSS)周期取消率及ET后OHSS发生率。结果:患者的基本情况组间无统计学差异(P0.05),B组Gn使用天数明显多于A组(P0.05),Gn总用量明显多于A组(P0.05),hCG注射日E_2、LH组间无统计学差异(P0.05),B组hCG注射日孕酮(P)值显著高于A组(P0.05);获卵数B组显著多于A组(P0.05),受精率、卵裂率、移植胚胎数组间无统计学差异(P0.05),但优质胚胎率B组却显著低于A组(P0.05),移植患者临床妊娠率组间差异无统计学意义(P0.05),A组仅稍高于B组。A组预防OHSS周期取消率较B组明显下降(P0.05),B组移植患者OHSS发生率略高于A组(P0.05)。结论:在卵巢次高反应患者人群中从启动日添加HP-hMG能改善胚胎质量,增加子宫内膜容受性,降低OHSS发生率。     

基础FSH/LH比值及晚卵泡期LH水平对体外受精-胚胎移植结局的影响

目的:探讨患者基础FSH/LH比值及控制性超促排卵(COH)时降调后hCG注射日血清LH水平对IVF-ET结局的影响及与COH各参数的关系。方法:回顾性分析首次进行IVF/ICSI-ET助孕、应用GnRH-a长方案降调节的不孕妇女,共427个周期。结果:ROC曲线显示FSH/LH比值与IVF-ET临床妊娠率无明显相关性;FSH/LH≥2与FSH/LH<2组间虽然临床妊娠率无差异,但FSH/LH≥2组Gn用量增加,获卵数少,优质胚胎数少,存在统计学差异(P<0.05)。hCG注射日血清LH≥0.65IU/L者妊娠率(55.8%)明显高于LH<0.65IU/L者(24.6%)。结论:基础FSH/LH比值增高能较早反映卵巢储备功能并指导超排方案及Gn用量;降调节后卵泡晚期(hCG注射日)的LH水平过低(<0.65IU/L),将会导致临床妊娠率下降。     

微刺激促排卵方案在PCOS患者IVF中的应用

目的:探讨微刺激促排卵方案在多囊卵巢综合征(PCOS)患者IVF中的应用。方法:将行IVF-ET的不孕患者分为3组:PCOS长方案组(A组,n=31)、PCOS微刺激组(B组,n=23)和非PCOS长方案对照组(C组,n=25)。比较3组的年龄、不孕年限、基础内分泌、口服避孕药后基础内分泌及IVF结局。结果:①年龄、不孕年限、基础FSH(bFSH)组间比较均无统计学差异(P>0.05);bLH、bLH/bFSH、bT在A组和B组中均明显高于C组(P<0.05);用口服避孕药后A组和B组LH、LH/FSH、T明显降低,使3组间内分泌比较无统计学差异(P>0.05)。②A组的受精率、卵裂率低于C组(P<0.05);Gn使用天数、获卵数、可利用胚胎数、优质胚胎数高于C组(P<0.05);Gn使用总量、种植率、临床妊娠率、流产率A、C组间比较均无统计学差异(P>0.05)。③B组受精率、卵裂率低于C组(P<0.05);Gn使用总量及Gn使用天数比C组明显减少(P<0.05);获卵数、可用胚胎数、优质胚胎数高于C组(P<0.05);B、C组间种植率、临床妊娠率、流产率比较无统计学差异(P>0.05)。④B组Gn使用总量及Gn使用天数比A组明显减少(P<0.05);B组获卵数、受精率、卵裂率、优质胚胎数、可利用胚胎数等指标与A组比较均无统计学差异(P>0.05)。⑤B组hCG注射日E2水平及移植日子宫内膜厚度明显低于A组(P<0.05),但种植率、临床妊娠率、流产率等方面与A组比较均无统计学差异(P>0.05)。结论:①口服避孕药在调整PCOS患者内分泌,降低PCOS患者LH、T方面有较好的作用,能改善PCOS患者内分泌环境;②PCOS患者行IVF时采用克罗米酚(CC)加hMG微刺激可降低hCG注射日E2水平,减少OHSS的发生。③CC加hMG微刺激方案对PCOS患者行IVF促排卵可能是相对经济、有效、安全的方法。     

体外受精超促排卵治疗中单用促性腺激素和拮抗剂方案临床结局的比较

目的探讨体外受精(IVF)治疗中单用促性腺激素(Gn)对妊娠结局的影响。方法月经第3日开始给予重组卵泡刺激素(rFSH)促排卵,促排卵第6日开始监测血激素水平和阴道超声监测卵泡大小。将达到思则凯添加标准者[黄体生成素(LH)5 IU/L,或LH/基础LH≥3]设为对照组,每日给予思则凯0.125 mg直至人绒毛膜促性腺激素(hCG)注射日;以未达到标准不使用思则凯者设为研究组。结果研究组(n=31)和对照组(n=49)患者在Gn剂量、促排卵天数、hCG注射日血清内分泌水平、获卵数、受精率、着床率、临床妊娠率和活产率方面均无统计学差异(P0.05)。结论在IVF促排卵治疗中,通过对血清LH的监测,如果LH维持在低水平可以不给予拮抗剂治疗,单纯使用Gn是一种经济有效的促排卵方案。     

透明带形态异常卵母细胞在IVF完全受精失败后行补救ICSI的临床结局

目的:研究透明带形态异常卵母细胞的受精、胚胎发育和临床结局。方法:以在IVF完全受精失败(TFF)周期中透明带形态异常的15名患者为研究组(A组),非透明带形态异常的完全受精失败周期的63例患者为对照组(B组),回顾性分析比较患者的一般临床情况、IVF结局及行补救ICSI(R-ICSI)的临床结局。结果:除受精率组间有显著性差异(65.52%vs 78.86%,P<0.01)外,其余各指标(年龄、不孕年限、不孕类型、不孕原因、基础内分泌水平、基础卵泡数、降调节天数、Gn使用天数、Gn使用总量、hCG注射日直径≥16 mm卵泡数、hCG注射日E2、P和LH水平、获卵数、MII卵数、行R-ICSI的受精率、卵裂率、优质胚胎率、种植率、临床妊娠率和流产率)组间均无统计学差异。结论:IVF完全受精失败周期透明带形态异常卵母细胞行R-ICSI虽受精率较低,但及早发现受精失败并行R-ICSI,可使65.52%的卵子受精,从而改善临床结局。     

控制性超排卵长、短方案在IVF-ET中的疗效比较

目的:比较促性腺激素释放激素激动剂(GnRHa)长、短方案控制性超排卵在体外受精-胚胎移植(IVF-ET)中的疗效。方法:将2001年7月-2002年4月因双侧输卵管梗阻IVF-ET的患者100人随机分为长方案组(50人)和短方案组(50人)进行超排卵。长方案组从使用促性腺激素(Gn)治疗前1月经周期黄体期(月经21天)使用GnRHa 0.3mg/d,至垂体完全降调节后加用Gn;短方案组从月经周期第2天开始用GnRHa0.1mg/d,同时加用Gn。当患者有3个以上卵泡直径>18mm时肌肉注射人绒毛膜促性腺激素(HCG),36小时后取卵行IVF,取卵48小时后行ET。结果:两组患者平均获卵数、受精率、卵裂率、优质胚胎率、移植胚胎数、临床妊娠率、胚胎种植率及流产率差异无显著性。而两者的Gn使用量有差别,短方案组少于长方案组,两组差异有显著性。两组用Gn第7天雌激素水平不同,短方案组明显高于长方案组,两者差异有显著性。结论:GnRHa长、短方案在IVF-ET中控制性超排卵效果相同,但所需Gn数量不同。     

拮抗剂方案中应用促性腺激素释放激素激动剂联合人绒毛膜促性腺激素诱导卵泡成熟的结局分析

目的:探讨拮抗剂方案中联合应用促性腺激素释放激素激动剂(Gn RHa)及人绒毛膜促性腺激素(h CG)在接受体外受精/卵胞质内单精子注射-胚胎移植(IVF/ICSI-ET)的患者中诱导卵泡成熟的疗效。方法:共纳入拮抗剂方案促排卵行IVF/ICSI的不孕症患者392例,根据诱导卵泡成熟方法分为Gn RHa联合h CG组(A组,194例)及单用h CG组(B组,198例),观察并计算胚胎情况、妊娠结局及中重度卵巢过度刺激综合征(OHSS)发生率。结果:患者年龄、基础FSH水平、窦卵泡数、促性腺激素(Gn)总使用天数和h CG注射日雌二醇(E2)水平组间差异无统计学意义(P0.05),A组的卵子成熟率显著高于B组(P0.05);A组的双原核(2PN)受精率、第3日(D3)优质胚胎率及囊胚形成率均高于B组,差异无统计学意义(P0.05);生化妊娠率、临床妊娠率、活产率及中重度OHSS发生率组间差异均无统计学意义(P0.05)。结论:拮抗剂方案中联合应用Gn RHa及h CG诱导卵泡成熟可改善卵子成熟度,进而可能改善胚胎质量。     

基础FSH/LH比值对预测年轻不孕患者IVF-ET周期卵巢反应性的影响

目的:探讨基础FSH和LH比值预测基础FSH水平正常且年轻不孕患者卵巢反应性的临床价值。方法:回顾分析2004年6月至2005年5月因男方因素或输卵管因素行体外受精-胚胎移植(in-vitrofertilization-embryotransfer,IVF-ET)治疗的年轻(年龄≤35岁)且基础FSH水平正常(≤8.5IU/L)不孕患者237例的临床资料,共计237个治疗周期,依据FSH/LH不同比例分为3组,A组(n=44)FSH/LH<1;B组(n=143)FSH/LH12;C组(n=50)FSH/LH>2。比较各组间的年龄、激素水平、卵巢反应、IVF的实验室结果以及妊娠情况。结果:3组患者的年龄、窦卵泡数、基础E2值、受精率、卵裂率和妊娠率两两相比无统计学差异(P>0.05),但A、B两组间的基础FSH值、基础LH值、E2峰值和成熟卵泡数差异有统计学意义(P<0.05);A、C两组间基础FSH值、基础LH值、E2峰值、促性腺激素(gonadotropin,Gn)总用量、Gn平均每日用量、Gn用药时间及获卵数和成熟卵泡数的差异有统计学意义(P<0.05);B、C两组间基础LH值、E2峰值、促性腺激素总用量、Gn平均每日用量和Gn用药时间比较也有明显差异(P<0.05)。结论:FSH正常的年轻妇女,FSH/LH>2的卵巢反应性明显低于FSH/LH<1者;FSH/LH比值是预测基础FSH正常且年轻不孕者卵巢反应性的一项较好指标。     

Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome

Abstract

The aim of this study was to compare GnRHa trigger and luteal addition of triptorelin to hCG trigger for final oocyte maturation in women at high risk for OHSS undergoing IVF. A total of 423 patients were divided in two groups both stimulated using antagonist short protocol. Gonadotropins 75–150 UI/day were started on day 2–5, GnRH antagonist was added when the lead follicle was >14?mm and the final trigger was obtained with hCG 250?µg or triptorelin 0.2?mg. The luteal phase was supported with progesterone alone in the hCG group, with progesterone plus triptorelin 0.1 every other day from embryo transfer in the triptorelin group. In the triptorelin group we did neither have to suspend any embryo transfer, nor we have any early clinical OHSS. In the control group, 13 patients were suspended due to symptomatic high risk for OHSS and two patients developed a clinically significant OHSS. No statistically significant difference was observed in terms of clinical and ongoing pregnancy rates and implantation rates. Our results indicate that a protocol including GnRHa as trigger and an intensive luteal phase supported with GnRHa is safer than a standard antagonist protocol using hCG as trigger. It displays similar results, therefore it can be used as the first choice in patients at high risk for OHSS.     

A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation

Recently, several new promising modifications have been introduced to clinical practice that may simplify and optimize IVF outcome. In the present opinion paper we present a simplified approach to controlled ovarian hyperstimulation protocol (COH), which combines the benefits of the ultrashort flare GnRH agonist/GnRH antagonist protocol and the personalized tailored mode and timing of ovulation triggering, aiming to improve IVF outcome while eliminating of severe OHSS.In patients at risk to develop severe ovarian hyperstimulation syndrome (OHSS), GnRH agonist (GnRHa) trigger if offered for final follicular maturation. While in those achieving ≥20 oocytes, the freeze all policy with the subsequent frozen-thawed embryo transfers (ET) is recommended, in those where less than 20 oocytes are retrieved, patients are re-evaluated 3 days after oocyte retrieval (day of ET) for signs of early moderate OHSS. If no early signs of OHSS developed, one embryo was transferred, and the patients are instructed to inject 1500 IU of HCG. In cases where signs of early moderate OHSS appear, the freeze all policy is recommended.In Patients not at risk to develop severe OHSS- three different modes of concomitant administration of both GnRHa and a standard bolus of hCG (5000–10,000 units) prior to oocyte retrieval were suggested. Standard hCG dose concomitant with GnRHa (dual trigger), 35–37 h before oocyte retrieval is offered to normal responders patients, resulting in improved oocyte/embryo quality and IVF outcome. GnRHa 40 h and standard hCG added 34 h prior to oocyte retrieval (double trigger), respectively are offered to patients demonstrating abnormal final follicular maturation despite normal response to COH. The double trigger results in significantly higher number of oocytes retrieved, higher proportions of the number of oocytes retrieved to the number of follicles >10 mm and >14 mm in diameter on day of hCG administration, higher number of MII oocytes and proportion of MII oocytes per number of oocytes retrieved, with the consequent significantly increased number of top-quality embryos, as compared to the hCG-only trigger cycles. Standard hCG dose concomitant with GnRHa (dual trigger), 34 h before oocyte retrieval should be offered to poor responders patients, aiming to overcome premature luteinization, while achieving high yield of mature oocytes.Further studies are required to support this new concept prior to its implementation as a universal COH protocol to IVF practice.     

GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at ‘freeze-all strategy’

A case is reported of early onset ovarian hyperstimulation syndrome (OHSS) after gonadotrophin-releasing hormone agonist (GnRHa) trigger for final oocyte maturation in a GnRH antagonist protocol. The use of GnRHa in place of HCG as a trigger for final oocyte maturation in an antagonist IVF cycle has been proposed as a method for preventing OHSS in predicted high-responders. This approach, however, did not prevent the occurrence of OHSS in our case despite a freeze-all strategy. To the best of our knowledge, this is a possible index case of severe OHSS with GnRHa trigger for oocyte maturation without any luteal HCG rescue for a high responder, despite IVF cycle segmentation.     

GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS

The aim of this retrospective study was to evaluate the effectiveness of gonadotrophin-releasing hormone agonist (GnRHa) to trigger oocyte maturation in patients with polycystic ovarian syndrome (PCOS) or previous high response. The outcome of ovarian stimulation and IVF in patients using GnRHa to trigger oocyte maturation after co-treatment with GnRH antagonist (study group) was compared with patients using human chorionic gonadotrophin (HCG) to trigger oocyte maturation after a dual pituitary suppression protocol with oral contraceptive pill (OCP) and GnRHa overlap (control group). All patients received intramuscular progesterone for luteal support but patients in the study group received additional supplementation with oestradiol patches. The mean number of oocytes, proportion of mature oocytes and fertilization rate were similar between the study and control groups. Implantation rate (38.6% versus 45.1%), clinical pregnancy rate (69.6% versus 60.9%) and delivery rate (62.5% versus 56.5%) were similar in the study and control groups respectively. There was one case of moderate ovarian hyperstimulation syndrome (OHSS) in the control group and none in the study group. GnRHa is effective in triggering oocyte maturation in patients with PCOS or previous high response. Further randomized studies are required to evaluate its effectiveness in the prevention of OHSS in this group of patients.     

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience

Purpose

To analyze the cycle outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS), when oocyte maturation was triggered by gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation.

Methods

One hundred twenty-nine women aged?≤?45 years, diagnosed with stage?≤?3 breast cancer, with normal ovarian reserve who desired fertility preservation were included in the retrospective cohort study. Ovarian stimulation was achieved utilizing letrozole and gonadotropins. Oocyte maturation was triggered with GnRHa or hCG. Baseline AMH levels, number of oocytes, maturation and fertilization rates, number of embryos, and the incidence of OHSS was recorded.

Results

The serum AMH levels were similar between GnRHa and hCG groups (2.7?±?1.9 vs. 2.1?±?1.8; p?=?0.327). There was one case of mild or moderate OHSS in the GnRHa group compared to 12 in the hCG group (2.1 % vs. 14.4 %, p?=?0.032). The maturation and fertilization rates, and the number of cryopreserved embryos were significantly higher in the GnRHa group.

Conclusions

GnRHa trigger improved cycle outcomes as evidenced by the number of mature oocytes and cryopreserved embryos, while significantly reducing the risk of OHSS in breast cancer patients undergoing fertility preservation.     

The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation

Polycystic ovary syndrome (PCOS) patients are prone to develop ovarian hyperstimulation syndrome (OHSS), a condition which can be minimized or completely eliminated by the use of a gonadotropin-releasing hormone agonist (GnRHa) trigger. In this commentary paper, we maintain that the gonadotropin-releasing hormone antagonist protocol should be the protocol of choice for the PCOS patient undergoing ovarian stimulation with gonadotropins for in vitro fertilization. If an excessive ovarian response is encountered, the clinician will always have two options: either to trigger final oocyte maturation with a bolus of GnRHa and supplement the luteal phase with a small bolus of human chorionic gonadotropin in addition to the standard luteal phase support and transfer in the fresh cycle or, alternatively, to trigger with GnRHa and perform a total freeze, resulting in a complete elimination of OHSS and high ongoing pregnancy rates in the subsequent frozen-thawed transfer cycles.     

来曲唑预防取卵术后卵巢过度刺激综合征的临床效果研究

目的:探讨卵巢过度刺激综合征(OHSS)高危人群在取卵术后,口服来曲唑预防OHSS发生的临床效果。方法:回顾性分析厦门市妇幼保健院2011年11月至2016年5月行体外受精-胚胎移植(IVF-ET)助孕,使用(GnRH-a)长方案或超长方案超促排卵,因预防OHSS取消移植,行全胚冷冻患者621例,按照是否于取卵术后口服来曲唑分为两组。一组于取卵术后未口服来曲唑(对照组),共298例;另一组于取卵术后口服来曲唑(研究组),共323例。对比两种方案患者助孕情况和OHSS的发生率、中重度OHSS的发生率。结果:研究组323例患者中OHSS的发生率为15.17%,显著低于对照组(P0.05)。研究组中重度OHSS的发生率为4.64%,也显著低于对照组(P0.05)。研究组促性腺激素(Gn)总量、Gn总天数、HCG日的雌二醇(E2)、黄体生成激素(LH)、孕酮(P)和获卵数与对照组比较差异无统计学意义(P0.05)。结论:来曲唑可以更好地降低高危人群在取卵术后OHSS的发生率及中重度OHSS的发生率。临床上可以考虑将来曲唑作为预防OHSS的药物使用。     

GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome

A retrospective, cohort study of high-risk patients undergoing IVF treatment was performed to assess if there is a difference in clinical pregnancy rate, live birth rate and the incidence of ovarian hyperstimulation syndrome, when a GnRH agonist (GnRHa) trigger with intensive luteal support is compared to human chorionic gonadotropin (hCG) with standard luteal support. The control group consisted of 382 high-risk patients having a GnRH antagonist protocol with 194 receiving an hCG trigger. All patients had?≥18 follicles?≥11mm or serum oestradiol?>18,000pmol/l on the day of trigger. Patients had a single or double embryo transfer at cleavage or blastocyst stage. Logistic regression was used to adjust for differences between the groups. An intention-to-treat analysis of all cycles was performed. No statistically significant differences were observed in terms of positive pregnancy test, clinical pregnancy rate and live birth rate. Only one patient (0.3%) was hospitalized with severe OHSS in the GnRHa group, compared to 26 patients (13%) in the hCG group. In conclusion, GnRHa trigger is associated with similar pregnancy rates with hCG trigger and a significant reduction in hospitalization for severe OHSS after an intention to treat analysis was performed.     

Individual luteolysis post GnRH-agonist-trigger in GnRH-antagonist protocols

Over the past few years, the use of Gonadotropin-releasing-hormone (GnRH)-agonist for final oocyte maturation in GnRH-antagonist-protocols in stimulated IVF/ICSI cycles has gained worldwide acceptance, as this approach reduces significantly the risk for development of ovarian hyperstimulation syndrome (OHSS). Final oocyte maturation with GnRH-agonist leads to sever luteolysis, which cannot be counterbalanced using standard luteal phase support with purely progesterone (P4) application and therefore administration of hCG or high doses of P4 is considered to be essential to prevent/counteract luteolysis. However, lately publications indicate, that luteolysis is not always complete after GnRH-agonist for trigger. This case-series evaluates the degree of luteolysis in high-responder-patients, who received GnRH-agonist for final oocyte maturation. Assessment of estradiol (E2)- and P4-levels 48?h after oocyte-pick-up (OPU) procedure demonstrate clearly, that luteolysis after GnRH-agonist trigger is individual-specific, even in high-responder patients with the same number of oocytes. Hence, individualization of luteal phase support with the focus on avoiding unnecessary administration of hCG, bearing the risk for development of OHSS, a new concept of luteal coasting needs to be developed, based on severity of luteolysis following luteal coasting.